Legend Biotech Corporation (LEGN)
USD 30.77
(1.72%)
USD 30.77
(1.72%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -384.46 Million | -200.02 Million | -198.46 Million | -223 Million | -83.06 Million | 307.68 Million |
| Net Income | -518.25 Million | -445.72 Million | -386.2 Million | -307.62 Million | -130.37 Million | -1.61 Million |
| Depreciation & Amortization | 20.45 Million | 18.39 Million | 13.91 Million | 9.93 Million | 5.26 Million | 1.68 Million |
| Deferred income taxes | -212.97 Million | - | -174.94 Million | 9.22 Million | -7.35 Million | -5.66 Million |
| Stock-based compensation | 47.68 Million | 34.33 Million | 20.15 Million | 4.76 Million | 1.27 Million | 704 Thousand |
| Change in working capital | -71.32 Million | 186.31 Million | 140.86 Million | -23.91 Million | 52.48 Million | 318.7 Million |
| Other non-cash items | 349.94 Million | 6.64 Million | 187.74 Million | 84.61 Million | -4.35 Million | -6.13 Million |
| Investing Cash Flow | 83.97 Million | -78.34 Million | -194.98 Million | -24.16 Million | -58.65 Million | -102.25 Million |
| Investments in PPE | -121.5 Million | -22.27 Million | -47.11 Million | -49.77 Million | -39.17 Million | -21.02 Million |
| Acquisitions | - | - | 3.2 Million | 4.02 Million | -460 Thousand | 20 Thousand |
| Investment purchases | -4.86 Billion | -654.97 Million | -377.95 Million | -72.68 Million | -390.39 Million | -6 Million |
| Sales/Maturities of investments | 5.06 Billion | 613.6 Million | 230.08 Million | 98.28 Million | 320.85 Million | - |
| Other Investing Activities | 907 Thousand | -14.7 Million | -3.2 Million | -4.02 Million | 50.52 Million | -75.23 Million |
| Financing Cash Flow | 791.49 Million | 377.97 Million | 626.66 Million | 618.87 Million | 14.66 Million | 2.5 Million |
| Debt repayment | -3.75 Million | -2.59 Million | -1.41 Million | -2.6 Million | -7.92 Million | -219 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 795.24 Million | 377.64 Million | 623.44 Million | 462.08 Million | - | - |
| Other Financing Activities | 795.24 Million | 2.92 Million | 4.64 Million | 159.39 Million | 22.58 Million | 2.72 Million |
| Accounts receivables | -98.98 Million | 50.32 Million | 24.59 Million | -45 Million | -3.77 Million | 207.6 Million |
| Accounts payables | -12.7 Million | 25.85 Million | 1.8 Million | -4.34 Million | 2.01 Million | 3.23 Million |
| Inventory | -12.7 Million | -8.6 Million | 51 Thousand | -643 Thousand | -22 Thousand | -1.12 Million |
| Other working capital | 53.06 Million | 118.75 Million | 114.42 Million | 26.07 Million | 54.26 Million | 108.98 Million |
| Cash at beginning of period | 787.3 Million | 688.93 Million | 455.68 Million | 83.36 Million | 210.16 Million | 2.11 Million |
| Cash at end of period | 1.27 Billion | 786.03 Million | 688.93 Million | 455.68 Million | 83.36 Million | 210.16 Million |
| Capital Expenditure | -121.5 Million | -22.27 Million | -47.11 Million | -49.77 Million | -39.17 Million | -21.02 Million |
| Effect of forex changes on cash | 682 Thousand | -2.51 Million | 34 Thousand | 620 Thousand | 249 Thousand | 124 Thousand |
| Net cash flow / Change in cash | 490.76 Million | 97.09 Million | 233.24 Million | 372.32 Million | -126.8 Million | 208.05 Million |
| Free Cash Flow | -505.97 Million | -222.3 Million | -245.57 Million | -272.78 Million | -122.23 Million | 286.66 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -18.19 Million | -59.79 Million | -518.25 Million | -144.81 Million | -62.49 Million | -198.83 Million |
| Depreciation & Amortization | 5.36 Million | 5.72 Million | 20.45 Million | 5.35 Million | 5.17 Million | 8.98 Million |
| Deferred income taxes | - | - | -212.97 Million | -124.36 Million | -1.23 Million | - |
| Stock-based compensation | 21.73 Million | 18.7 Million | 47.68 Million | 12.58 Million | 12.37 Million | 15.64 Million |
| Change in working capital | 9.57 Million | 94.04 Million | -71.32 Million | -11.57 Million | -1.79 Million | -19.81 Million |
| Other non-cash items | 2.06 Million | -107.64 Million | 349.94 Million | 169.58 Million | -12.86 Million | 113.93 Million |
| Investing Cash Flow | -696.81 Million | -396.81 Million | 83.97 Million | 405.1 Million | -209.07 Million | -123.58 Million |
| Investments in PPE | -20.57 Million | -22.78 Million | -121.5 Million | -25.41 Million | -5.47 Million | -10.36 Million |
| Acquisitions | - | - | - | 1.00 | -96 Thousand | - |
| Investment purchases | -1.47 Billion | -872.29 Million | -4.86 Billion | -1.91 Billion | -2.51 Billion | - |
| Sales/Maturities of investments | 796.2 Million | 498.27 Million | 5.06 Billion | 2.34 Billion | 2.33 Billion | - |
| Other Investing Activities | -17.15 Million | -16.54 Million | 907 Thousand | 906.99 Thousand | -26.18 Million | -113.21 Million |
| Financing Cash Flow | 954.99 Thousand | 831 Thousand | 791.49 Million | 925 Thousand | 961 Thousand | 789.89 Million |
| Debt repayment | -1.16 Million | -758 Thousand | -3.75 Million | -304 Thousand | -1.72 Million | -1.52 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 2.11 Million | 1.58 Million | 795.24 Million | 621 Thousand | 2.68 Million | - |
| Other Financing Activities | -1.16 Million | 1.58 Million | 795.24 Million | 608 Thousand | 2.68 Million | 789.89 Million |
| Accounts receivables | 6.5 Million | 80.46 Million | -98.98 Million | -99.05 Million | 15.04 Million | -14.97 Million |
| Accounts payables | -12.99 Thousand | 19.29 Million | -12.7 Million | 3.01 Million | -4.37 Million | 26.79 Million |
| Inventory | 5.03 Million | -4.47 Million | -12.7 Million | -5.04 Million | -2.81 Million | -4.84 Million |
| Other working capital | -1.95 Million | -1.25 Million | 53.06 Million | 89.5 Million | -9.64 Million | -26.79 Million |
| Cash at beginning of period | 897.93 Million | 1.27 Billion | 787.3 Million | 963.82 Million | 1.23 Billion | 660.05 Million |
| Cash at end of period | 201.68 Million | 897.93 Million | 1.27 Billion | 1.27 Billion | 963.47 Million | 1.23 Billion |
| Capital Expenditure | -20.57 Million | -22.78 Million | -121.5 Million | -25.41 Million | -5.47 Million | -10.36 Million |
| Effect of forex changes on cash | 9000.00 | -343 Thousand | 682 Thousand | 1.45 Million | -784 Thousand | 2.58 Million |
| Net cash flow / Change in cash | -696.24 Million | -380.14 Million | 490.76 Million | 314.24 Million | -269.74 Million | 573.16 Million |
| Free Cash Flow | -20.96 Million | -6.6 Million | -505.97 Million | -118.65 Million | -66.32 Million | -106.09 Million |
600649
HWAL
COPEC
MEDICAMEQ
3880
BHC